Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ESK-001-019

12 evidence topics · 1 source

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2026-01-30”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using placebo-adjusted change in QTcF as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
  • The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
  • The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
  • The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.